A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

<div>Survival analysis of patients with different treatment methods. OS of patients treated with (a) postrecurrence TACE, (b) adjuvant TACE, and (c) resection only. Recurrence-free survival (RFS) of patients treated with (d) postrecurrence or adjuvant TACE, (e) adjuvant TACE, and (f) resection only.</div>

Journal of Oncology

fig4

Figure 4

Figure 4: A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 

Figure 4 | A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 